Tscan Therapeutics, Inc. · NASDAQ:TCRX
Tscan Therapeutics — Corporate Update (June 2026)
48 slides from Tscan Therapeutics's corporate update, June 2026
Slide 1: Data from Cohort C of the Phase 1 ALLOHA Study
Data from Cohort C of the Phase 1 ALLOHA Study June 2026
Slide 2: Disclaimers and forward-looking statements
Disclaimers and forward-looking statements This presentation and the accompanying discussion contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding TScan Therapeutics, Inc.’
Slide 3: TScan is a fully integrated, next-generation TCR-T cell therapy company
TScan is a fully integrated, next-generation TCR-T cell therapy company Clinical HEME MALIGNANCY PROGRAM • Designed to treat residual disease and prevent relapse in patients undergoing bone marrow transplant • TSC-101 continues to be well-tolerated • Durable long-term data for TSC-101: 100% (2/2) of
Slide 4: Agenda
Agenda Overview of Heme Program and Manufacturing Update Gavin MacBeath, Ph.D. Updated Data from Cohort C of Phase 1 ALLOHA Trial Gavin MacBeath, Ph.D., Ran Reshef, M.D., M.Sc. Phase 3 Trial Design (ALLOHA-2) Chrystal Louis, M.D., M.P.H. Market Opportunity for TSC-101 and Follow-on Product Candidate
Slide 5: Heme Malignancies: Targeting residual disease to prevent relapse
Heme Malignancies: Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 6: TScan is working to treat residual disease and prevent relapse in heme malignancies
TScan is working to treat residual disease and prevent relapse in heme malignancies Allogeneic hematopoietic cell transplant Current Standard (Allo-HCT) is the only potential cure for of Care patients with AML and MDS 38-44% of patients relapse within two years Unmet Medical following Allo-HCT with
Slide 7: TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer
TSC-101 is a TCR-T cell therapy designed to eliminate residual cancer and prevent relapse following Allo-HCT TSC-101 PATIENT HA-2 positive Residual Cancer cancer HA-2 cell Hematopoietic cell TCR-T cell negative HA-2 transplant infusion positive standard of care transplant Normal blood cell Collectio
Slide 8: Heme Program: TSC-101 Recap of ASH data
Heme Program: TSC-101 Recap of ASH data
Slide 9: ALLOHA, a multi-arm Phase 1 trial for TSC-101
ALLOHA , a multi-arm Phase 1 trial for TSC-101 in subjects with AML, ALL, and MDS (NCT05473910) Manufacturing TSC-101 TSC-101 apheresis Infusion 1 Infusion 2 Subject Donor HCT screening screening apheresis Treatment Arm Transplant + TSC-101 Day 0 Day +21 Day +61 Control Arm Transplant alone Pre-tran
Slide 10: Patients treated with TSC-101 have more durable remissions than control patients
Patients treated Pre-HCT with TSC-101 have more durable remissions than control patients Arm MRD 6 months 1 year 2 years 3 years TSC-101 DL 1 TSC-101 infusion p53mut P004-0001 TSC-101 DL2‡ P004-0005 Clinical intervention for TSC-101 DL2 P004-0006 concern for relapse TSC-101 DL3‡ P004-0008 TSC-101 DL
Slide 11: ALLOHA Phase 1 data support launch of pivotal trial in Q2 2026
ALLOHA Phase 1 data support launch of pivotal trial in Q2 2026 Meaningful long-term Attractive safety profile Long-term persistence benefit Infusions with TSC-101 were More TSC-101-treated patients TSC-101 identified in all well-tolerated with no DLTs remain relapse-free >1-year post- treated patien
Slide 12: Heme Program Update: Patients infused with commercial ready process (Cohort C)
Heme Program Update: Patients infused with TSC-101 manufactured with commercial ready process (Cohort C)
Slide 13: Optimized manufacturing process results in robust production with shorter time and lower COGs
Optimized manufacturing process results in robust production with shorter time and lower COGs Phase 1 Process: 17 Days DAY 1 DAY 2 DAY 6 DAY 9 DAY 14 DAY 17 Isolate Electro- Activate Expand Enrich Expand Harvest & PBMCs porate T-cells T-cells TCR-T cells TCR-T cells Freeze Magnetic bead selection In
Slide 14: Patients are generally well balanced across arms
Patients are generally well balanced across arms, although Cohort C included a higher percentage of patients with MRD-positive disease prior to transplant TSC-101 TSC-101 Control Cohort A Cohort C Evaluable Subjects* 19 14 19 Age, Median years (Range) 65 (52-74) 68 (28-79) 66 (23-77) Sex, Male 13 (6
Slide 15: TSC-101 continues to be well-tolerated in Cohort C
TSC-101 continues to be well-tolerated in Cohort C TSC-101 Control* Cohort C n=19 n=14 Treatment-emergent aGvHD (MAGIC) 2 (14%) 12 (63%) • Safety has been consistent with Cohort A Grade I 1 (7%) 6 (32%) • One case of acute respiratory distress syndrome (ARDS) with TSC-101 Grade II 1 (7%) 5 (26%) •
Slide 16: TSC-101 is designed to eliminate residual cancer and prevent relapse following Allo-HCT
TSC-101 is designed to eliminate residual cancer and prevent relapse following Allo-HCT Post-transplant patient TSC-101 TCR-T cell infusion Residual nonmalignant Residual cancer cell cell (HA-2 positive) (HA-2 positive) Normal, donor- TSC-101 derived blood cell (HA-2 negative) HA-2 TCR T-cell 16
Slide 17: Donor chimerism serves as an early surrogate of efficacy
Donor chimerism serves as an early surrogate of efficacy Post-transplant patient Complete donor chimerism Mixed donor chimerism (low risk of relapse1,2) (increased risk of relapse1,2) Malignant, patient-derived blood cell Nonmalignant, patient-derived blood cell Normal, donor- Normal, donor- derived
Slide 18: Patients with complete donor chimerism have a low probability of relapse
Patients with complete donor chimerism using NGS chimerism assay at two months post-transplant have a low probability of relapse Mixed donor chimerism Probability of relapse Complete donor chimerism Time post-transplant (Days) Chimerism status of initial ALLOHA patients at 2 months post-transplant p
Slide 19: All but one patient in Cohort C responded with decreasing recipient chimerism
All but one patient in Cohort C (93%) responded to TSC-101 with decreasing recipient chimerism Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 p53-AML MDS MECOM-AML AML p53-ALL p53-MDS AML Dose level 4 Dose level 4 Dose level 3 Dose level 4 Dose level 4 Dose level 4 Dose level
Slide 20: Patients achieved complete donor chimerism within ~3 weeks of first infusion
11 of 14 patients achieved complete donor chimerism within ~3 weeks of receiving first infusion of TSC-101 04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 16-003 27-004 27-004 16-003 13-017 13-017 13-019 1 2 3 4 5 6 7 8 9 10 11 12 13 14 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 D
Slide 21: Patient with incomplete chimerism showed stabilization following third infusion
Patient with incomplete chimerism at day 105 showed stabilization following third infusion 1 2 3 4 5 6 7 8 9 10 11 12 13 14 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Time Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo Recipient chimerism Infusion 3 post
Slide 22: Patient with increasing recipient chimerism shows no morphologic evidence of disease
Patient with increasing recipient chimerism shows no morphologic evidence of disease by bone marrow biopsy 1 2 3 4 5 6 7 8 9 10 11 12 13 14 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo Recipient chimerism Time
Slide 23: Patient with p53-mutated ALL shows steady decrease in recipient chimerism
Patient with p53-mutated ALL shows steady decrease in recipient chimerism 1 2 3 4 5 6 7 8 9 10 11 12 13 14 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Recipient chimerism Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo Time post AML-p53 MDS AML AML ALL-p53
Slide 24: Patient with high recipient chimerism shows dramatic reduction after first infusion
Patient with high recipient chimerism post-transplant shows dramatic reduction following first infusion of TSC-101 1 2 3 4 5 6 7 8 9 10 11 12 13 14 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 DL4 Haplo Haplo MMUD Haplo Haplo MMUD Haplo MMUD MMUD Haplo Haplo Haplo MMUD Haplo Recipient chimeri
Slide 25: No patients in Cohort C have relapsed to date
No patients in Cohort C have relapsed to date, with higher rates of complete donor chimerism compared to control-arm patients % Patients with complete donor chimerism Cohort A Cohort C Control Immediately post-HCT 37% (7/19) 14% (2/14) 24% (4/17) ~3 weeks after infusion 1 79% (15/19) 79% (11/14) 61%
Slide 26: TSC-101 in Cohort C continues to show high levels of circulating TCR-T cells
TSC-101 in Cohort C continues to show high levels of circulating TCR-T cells TSC-101 levels following first infusion 1000000 TSC-101 (cells/mL blood) 100000 TSC-101 in Cohort C 10000 TSC-101 in Cohort A 1000 100 10 0 20 40 60 80 100 Infusion 1 Infusion 2 Time following first infusion (days) 26 Data
Slide 27: TSC-101 in Cohort C shows higher proliferation, activation, and cytotoxicity markers
TSC-101 in Cohort C shows higher markers of proliferation, activation, and cytotoxicity than in Cohort A Ki67 (proliferation) is higher in Cohort C CD28 (activation) is higher in Cohort C 2hr D7 2hr D7 100 80 ✱✱✱ ✱✱ 100 100 80 ✱✱✱✱ 60 80 ✱ % of TSC % of TSC 80 60 % of TSC 40 % of TSC 60 60 40 40 40
Slide 28: Heme Program: Review of Cohort C Data
Heme Program: Review of Cohort C Data
Slide 29: Patients are generally well balanced across arms
Patients are generally well balanced across arms, although Cohort C included a higher percentage of patients with MRD-positive disease prior to transplant TSC-101 TSC-101 Control Cohort A Cohort C Evaluable Subjects* 19 14 19 Age, Median years (Range) 65 (52-74) 68 (28-79) 66 (23-77) Sex, Male 13 (6
Slide 30: Patients achieved complete donor chimerism within ~3 weeks of first infusion
11 of 14 patients achieved complete donor chimerism within ~3 weeks of receiving first infusion of TSC-101 04-022 07-012 13-014 14-003 25-016 13-016 14-004 13-018 13-021 07-013 16-003 27-004 27-004 16-003 13-017 13-017 13-019 1 2 3 4 5 6 7 8 9 10 11 12 13 14 DL4 DL4 DL3 DL4 DL4 DL4 DL4 DL4 DL4 DL4 D
Slide 31: Heme Phase 3 trial design
Heme Phase 3 trial design Targeting residual disease to prevent relapse in patients undergoing allogeneic HCT
Slide 32: Pivotal trial design uses a biologically-assigned control arm
Pivotal trial design for TSC-101 uses a biologically-assigned control arm to support relapse-free survival as the primary endpoint • Agreement reached with the FDA to use a pivotal trial design that mirrors the ALLOHA Phase 1 trial • All patients that are eligible for TSC-101 will be assigned to the
Slide 33: Important protocol modifications from Phase 1 to Phase 3 study
Important protocol modifications from Phase 1 to Phase 3 study Phase 1 Phase 3 Population AML, ALL, MDS AML, MDS Haplo in Cohort A; Haplo and Donor Type Haplo and MMUD MMUD enrolled in Cohort C Treatment:Control 1:1 with flexibility Enrollment Ratio Treatment:Control ~1:1 up to ~1.5:1 Disease type &
Slide 34: Strategies developed to achieve balance between treatment and control arms
Strategies developed to achieve balance between treatment and control arms Goal: Balanced enrollment of high-risk vs. intermediate/low risk subjects between treatment and control arms Methods to Achieve Balance Enrollment Statistical Stratification by disease type and poor Separate models per diseas
Slide 35: US geographical footprint ensures appropriate patient access to treatment
US geographical footprint ensures appropriate patient access to treatment ATCs Color Coded by Category: Current clinical trial sites Potential additional sites for pivotal Potential additional sites for commercial • ~120 centers conduct allo-HCT • 21 sites in Phase 1 clinical trial • 30 sites in Pha
Slide 36: Heme program: HLA and indication expansion
Heme program: HLA and indication expansion
Slide 37: TCRs for additional HLA types will target epitopes on CD45
TCRs for additional HLA types will target epitopes on CD45, a universal source of antigens for heme malignancies • CD45 is a lineage-specific antigen with expression in all hematopoietic cells, including HSCs • CD45 is a large protein with many well-known epitopes for high frequency HLAs • Antigen-n
Slide 38: INDs cleared for TSC-102-A03 and TSC-102-A01; Phase 1 planned for Q4 2026
INDs cleared for TSC-102-A03 and TSC-102-A01; Phase 1 planned for Q4 2026 • Study expands the heme program – Two additional HLA types – MAC conditioning – ALL and Non-Hodgkin Lymphoma in addition to AML and MDS Indications Study Characteristics • AML, ALL, MDS • Dose escalation • Non-Hodgkin Lymphom
Slide 39: Continuous data read-outs over the next two years provides clinical de-risking
Continuous data read-outs over the next two years provides clinical de-risking • ALLOHA-2 Phase 3 trial will take ~2 years, with a topline readout targeted for mid-2028 • Cohort C uses the same manufacturing process as the ALLOHA-2 Phase 3 trial, and is expected to provide supportive data flow throu
Slide 40: Market opportunity
Market opportunity THERAPEUTICS
Slide 41: TSC-101 is incorporated seamlessly into current transplant journey
TSC-101 is incorporated seamlessly into current transplant journey HLA A*02:01-positive (HA-2-positive) * * Patient identification Day -10 to -1 Day 0 Day 21 Day 61 Follow up Reduced Intensity HCT transplant Infusion 1 Infusion 2 Conditioning with donor stem cells with engineered T cells with engine
Slide 42: At launch, ~2,350 patients will qualify for TSC-101 in the U.S.
At launch, ~2,350 patients will qualify for TSC-101 in the U.S. based on HLA type Addressable U.S. Patient Population ~7,000 AML/MDS patients estimated to undergo Allo HCT in 2029* 2,940 HLA-A*02:01 positive patients (42%) 2,350 with A*02-negative donor (80%) Requires transplant with reduced intensi
Slide 43: Market opportunity based on current transplant practice
Market opportunity based on current transplant practice Reduced intensity Myeloablative conditioning (RIC) conditioning (MAC) Other 4% Total transplants: ~2,350 per year Matched related 18% donors (MRDs) Matched unrelated 45% donors (MUDs) Haploidentical and mismatched unrelated 33% Current practice
Slide 44: Expansion opportunity 1: Positive data expected to induce changes in clinical practice
Expansion opportunity 1: Positive data expected to induce changes in clinical practice over time that increase the on-label use of TSC-101 Reduced intensity Myeloablative conditioning (RIC) conditioning (MAC) Other 4% Total transplants: ~2,350 per year Matched donors 63% (related and unrelated) Pote
Slide 45: Positive data expected to increase use of RIC and haplo/MMUD donors
Positive data expected to increase use of RIC and haplo/MMUD donors 7,000 6,000 # of addressable patients (US) 5,000 4,000 3,000 2,000 700 - 1,000 2,000 0 TSC-101 Source: SEER, CIBMTR, EBMT, APBMT; RIC, reduced intensity conditioning; Haplo, haploidentical donor; MMUD, mismatched unrelated donor 45
Slide 46: Expansion opportunity 2: Increased use of transplant
Expansion opportunity 2: Increased use of transplant provides a way to reach over 2,800 AML and MDS patients per year in the U.S. 7,000 6,000 # of addressable patients (US) 5,000 Expansion driven by increased rate of transplant 4,000 in AML and MDS: • + ~12% for AML +44% 3,000 • + ~9% for MDS ClearV
Slide 47: Expansion opportunity 3: Products that address additional HLAs
Expansion opportunity 3: Products that address additional HLAs more than double the potential patient population 7,000 Expansion driven by TSC-102 • HLA-A*03:01 Candidate HLA type Frequency +107% 6,000 • HLA-A*01:01 TSC-101 A*02:01 42% • HLA-A*24:02 # of addressable patients (US) TSC-102-A01 A*01:01
Slide 48: Q&A
Q&A